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Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of apoptosis. It
is frequently caused by mutations in FAS (TNFRSF6) gene. Unlike most of the self-
limiting autoimmune cytopenias sporadically seen in childhood, multi lineage cytopenias
due to ALPS are often refractory, as their inherited genetic defect is not going to go
away. Historically, more ALPS patients have died due to overwhelming sepsis following
splenectomy to manage their chronic cytopenias than due to any other cause, including
malignancies. Hence, current recommendations underscore the importance of avoiding
splenectomy in ALPS, by long-term use of corticosteroid-sparing immunosuppressive
agents like mycophenolate mofetil and sirolimus. Paradigms learnt from managing ALPS
patients in recent years is highlighted here and can be extrapolated to manage refractory
cytopenias in patients with as yet undetermined genetic bases for their ailments. It is also
desirable to develop international registries for children with rare and complex immune
problems associated with chronic multilineage cytopenias in order to elucidate their
natural history and long-term comorbidities due to the disease and its treatments.
Keywords: cytopenias, lymphoproliferative disorders, genetic disease, autoimmune lymphoproliferative syndrome,
autoimmune diseases
Introduction
Autoimmune lymphoproliferative syndrome (ALPS)1 is a disorder of the immune system due to
defective Fas-mediated apoptosis (1). Mutations in FAS (TNFRSF6) gene commonly cause what is
known as ALPS-FAS. Patients with undetermined genetic defect are classified as ALPS-U. ALPS
presents in childhood with lymphadenopathy, hypersplenism, and multilineage cytopenias. Many
patients experience a lessening of symptoms in adulthood,most likely due to age-associated immune
modulation. ALPS due to germline FAS mutations is inherited in an autosomal dominant manner
(2, 3), however somatic FAS mutations limited to circulating lymphocyte subsets leading to clinical
manifestations of ALPS have also been reported over the years (4–6). Of the estimated 1000 ALPS
patients reported thus far worldwide, over 300 participate in studies at the NIH Clinical Center.
Over many years of follow-up, the general morbidity attributable to ALPS includes the frequent
1http://www3.niaid.nih.gov/topics/ALPS/
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need for splenectomy and the risks of overwhelming post-
splenectomy infection (OPSI) leading to sepsis, recurrent and
chronic multilineage cytopenias, and development of lymphomas
(7, 8). Among ALPS-FAS patients, standardized incidence ratio
values are 149 and 61 times higher for Hodgkin and non-
Hodgkin lymphoma, respectively compared to US general popu-
lation. However, historically more ALPS-FAS patients have died
due to overwhelming sepsis following splenectomy to manage
their cytopenias than due to any other cause, including malig-
nancies and recently ALPS patients have been noted to have
a unique IgM-mediated immune surveillance defect following
exposure to pneumococci (7–9). Among the 66 splenectomized
patients in our recently published cohort, 41% (n= 27) had
multiple episodes of pneumococcal sepsis, and 6 of them died.
The likelihood of cytopenia relapse after splenectomy was 30%
by 4 years and exceeded 70% by 20 years thus underscoring the
futility of splenectomy itself as an intervention. Hence, current
recommendations based on published literature are highlighted
here (10, 11). Splenectomy should be avoided in ALPS patients
by using corticosteroid-sparing immunosuppressive agents like
mycophenolate mofetil (MMF) and sirolimus for the long-term
management of their concurrent or sequential cytopenias.
Treatment interventions that include ruling out malignancies
are indicated in ALPS patients at any age when they present
with clinically significant and refractory cytopenias. Clinicians
caring for these patients need to be familiar with their disease
course, vigilant for the complications including lymphoma devel-
opment, and wary of the long-term toxicity and accompanying
morbidity of any pharmacological intervention they might con-
template to undertake. It is hoped that paradigms learnt during
the last two decades fromdiagnosing andmanagingALPS as high-
lighted here can be applicable to other novel inherited immune
disorders presenting with nodal and extranodal lymphoprolifer-
ation, infection, end organ damage as well as T- and B-cell dys-
function leading to many autoimmune complications including
cytopenias (10, 12–16).
Diagnosis and Management of Cytopenias
in ALPS
Cytopenias due to underlying immunological disorders like sec-
ondary chronic immune thrombocytopenia (ITP) seen in SLE
patients have been known to present their own unique clinical
challenges which includes establishing an early diagnosis, ruling
out malignancies, and minimizing end organ damage while ren-
dering long-term care (17, 18). Diagnosis of ALPS should be based
on published criteria, which requires presence of lymphadenopa-
thy, splenomegaly, and increased (>2.5%) CD4-/CD8-double
negative TCR alpha/beta+ T cells in peripheral blood circulation,
the signature cells of ALPS. Other biomarkers including increased
serum vitamin B12, IgG, IL10, and very low HDL provide helpful
clues to search for a FASmutation leading to a diagnosis of ALPS-
FAS, by far the most well described and common subtype of
ALPS seen in nearly two-thirds of the cohorts worldwide (19–
22). We recently summarized our experience related to cytope-
nias in 150 patients with ALPS-FAS with a median follow-up of
13.5 years (8). Recurrent multilineage cytopenias were common,
seen in two-thirds (104/150) of them. Their median age of initial
presentation was 5.6 years with a range of age of disease onset
from 1 to 53 years. There were no gender differences. Single
lineage, bilineage, and trilineage cytopenias were seen in 21,
23, and 25% of them, respectively. Eighty-eight patients were
treated long-term for cytopenias, but their need for treatment
frequency appeared to decline with age. Pulse doses of corti-
costeroids, often the most effective immediate intervention was
given to 90% of them. However, most patients required multi-
ple agents that included long-term (>1 year) immunosuppression
using MMF, rapamycin (sirolimus), intravenous immunoglob-
ulin, rituximab, vincristine, cytoxan, hydroxychloroquine, 6MP,
and WinRho, although one individual developed severe hemol-
ysis after WinRho. This prompted us not to use WinRho for
ALPS patients thereafter, as many of them are already Coomb’s
DAT positive without overt hemolytic anemia. In the following
section, an updated narrative of the long-term experience so far
using immunosuppressive agents including MMF and sirolimus
for managing cytopenias and other autoimmune complications in
ALPS patients is presented (10, 16, 23).
Corticosteroids and many of the immunosuppressive drugs
including azathioprine, cyclosporine, or MMF, fail to reliably
shrink the spleen or lymph nodes in ALPS patients. Actually, no
intervention is usually indicated in many of these patients unless
and until they present with clinically significant cytopenias. These
can be due to splenic sequestration, bone marrow infiltration
with non-malignant lymphoproliferation consisting of clustering
islands of T and B lymphocytes, and/or autoimmune periph-
eral destruction of blood cells in the reticuloendothelial system.
Hence, systemic symptoms such as fever, fatigue, weight loss, loss
of appetite, and/or sudden focal lymph node enlargement should
be carefully evaluated and lymphoma should be ruled out in the
clinical context prior to embarking on definitive treatments for
cytopenias using immunosuppressive agents. The initial manage-
ment autoimmune cytopenias including autoimmune hemolytic
anemia (AIHA), immune-mediated thrombocytopenia, autoim-
mune neutropenia in ALPS patients is not much different from
management of sporadic immune cytopenias in other patient
populations (24). Following principles are outlined specifically as
a guideline for ALPS patients with refractory cytopenias based
on our experience derived from managing them over the last
15 years. Many patients included here and summarized in Table 1
have been exposed to multiple agents sequentially as described
below.
Immune Suppression with Corticosteroids
High-doses of pulse therapy should be initiated with intravenous
methylprednisolone (5–10mg/kg 7–10 days). This should be
followed by oral prednisone (1–2mg/kg) as a maintenance
therapy that can be tapered over a period of several weeks
(8–12weeks). Higher doses of intravenous methylprednisolone
(up to 30mg/kg per day for 1–3 days) may have to be used in
for severe and refractory cytopenias (e.g., very low hemoglobin of
<5 g/dL).Usual steroid-related comorbidities including hyperten-
sion, hyperglycemia, cataracts, osteopenia, and avascular necrosis
of the hip as well as Cushingoid body habitus has prompted us to
avoid their long-term use.
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TABLE 1 | Cytopenia treatment outcomes in ALPS patients.
Patients MMF
(n=64)
Sirolimus
(n=14)
Rituximab
(n=26)
Hydroxychloroquine
(n=4)
TPO mimetics
(Eltrombopag and Nplate) (n=4)
ALPS-FAS 45 12 20 4 3
ALPS-U 19 2 6 1
Gender ratio (male/female) 49:15 10:4 20:6 2:2 3:1
Median age at start of
medication (range)
10 years (0.5–34 years) 2 years (1–37 years) 13 years (1–47 years) 17 years (12–30 years) 19 years (9–20 years)
Median duration of follow-up
on medication (range, years)
4.5 years (0.5–l5 years) (0.5–6 years) NA 3 years (0.5–7 years) 2.25 (0.5–4 years)
Long-term responders 44 10 16a 2 2
Non-responders (requiring
other interventions)
20 4 10 2 2
aRemission lasted at least 6months after one course of rituximab 375mg/M2 weekly 4.
Intravenous Immunoglobulin G
Intravenous immunoglobulin G (1-2g/kg/day 2 days) is usually
given concomitantly with pulse dose IVmethylprednisolone. This
helps some patients with severe AIHA or ITP as IVIG uptake by
the reticuloendothelial system in the spleen, liver, and bone mar-
row reduces antibody-mediated red cell and/or platelet destruc-
tion. This also sustains packed red blood cell transfusion support
toward relief of anemia in the setting of active ongoing hemolysis.
Role of Granulocyte Colony Stimulating Factor
in Isolated Neutropenia
Twice or thrice weekly, very low dose G-CSF (1–2mcg/kg)
given subcutaneously may benefit some ALPS patients. How-
ever, G-CSF should only be reserved for treating isolated neu-
tropenia with associated infections in patients without significant
splenic enlargement in order to avoid possibility of further G-CSF
induced splenic enlargement and rupture. It is always prudent to
check CBCs to rule out neutropenia and provide antibiotic pro-
phylaxis as needed before dental work and other elective surgeries
in some of these patients with significant neutropenia.
Mycophenolate Mofetil
We described our experience using MMF for treating chronic
cytopenias in 13 children with ALPS in 2005 (13). MMF, given
twice daily orally (600mg/m2 per dose), has enabled us to avoid
chronic steroid usage in many patients with ALPS-associated
refractory cytopenias over the last 15 years.We have usedMMF in
64 ALPS patients (median age 10 years with a range of 6months
to 15 years) as ongoing long-term steroid sparing immune sup-
pression. These patients have had a median follow-up of 4.5 years
(range, 6months to 15 years) in our clinic. Most of them have
chronic and refractory cytopenias. Some of them also have other
autoimmune manifestations, such as uveitis, hepatitis, glomeru-
lonephritis, and infiltrative pulmonary lesions. Notably 18 of
them have had their cytopenias relapse following splenectomy
prior to commencing treatment with MMF. Most patients (60/64)
responded to MMF. Their response was predicated by adequate
hemoglobin, neutrophil, and platelet counts. In responders, we
could reduce dose or stop other immunosuppressive agents for at
least 1 year. However, 20 of them required other therapies (includ-
ing switch to sirolimus in 7 of themwith hypersplenism) later on as
their cytopenias became more refractory. One ALPS-FAS patient
developed Hodgkin’s lymphoma, but he continues to require
MMF for cytopenia for the last 9 years; another patientwithALPS-
Uwhile onMMF for 8 years underwent bonemarrow transplanta-
tion for acute leukemia and he is no longer requiring MMF as his
cytopenias have resolved. One ALPS-FAS patient after a period of
response to MMF for 5 years had overwhelming AIHA and died.
MMF has also allowed splenectomy to be avoided or postponed in
three patients. These very young children seem to have tolerated
splenectomy with no OPSI when they were subjected to the same
as older children. Five patients are considered lost to follow-up as
their return visit to our clinic has been more than 5 years ago.
Rapamycin (Sirolimus)
Rapamycin, an mTOR inhibitor, has been used successfully in
ALPS patients as first reported by Teachey et al. (23). ALPS-
FAS patients with enlarged lymph nodes and spleen may require
and benefit from rapamycin. Their cytopenias are usually refrac-
tory. Most ALPS patients on rapamycin show a good response
in terms of reduction of lymphoproliferation as lymph nodes
and spleen often shrink significantly. Many of the biomarkers
including the signature DNT cells, serum IL10, serum vitamin
B12 as well as HDL values normalize (20). Patients should be
started with the initial loading dose of sirolimus (3mg/m2), they
can then be maintained with a dose of 2.5mg/m2 given once a
day (up to a maximum daily dose of 4 or 5mg). Twenty-four-hour
trough drug level of 5–15 ng/mL should be the target. Younger
children may need a more frequent Q12 hourly dosing as they
metabolize sirolimus more briskly than adults. It is critical to
monitor for toxic side effects of sirolimus on kidney and liver
function, and be wary of T-cell immunosuppression, hypercholes-
terolemia, and stomatitis. So far, we have used sirolimus in 14
individuals in our cohort, including mostly ALPS-FAS (n= 12)
patients as a long-term steroid sparing measure. Their median
age at treatment initiation has been 2 years (range 1–37 years)
with a treatment duration spanning 6months to 6 years. Four
patients have discontinued therapy due to ineffectiveness of
sirolimus and two adult patients have been weaned off of all the
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medications including rapamycin successfully due to resolution
of their cytopenias.
Rituximab
Rituximab (375mg/m2 per week 4) has also been used in 26
ALPS patients in our cohort as a treatment for their cytopenias.
Most of them have received these treatments at outside hospitals,
many before evenALPS could be suspected as a possible diagnosis.
Sixteen patients responded with stable counts for at least 6months
and seven of them with ITP had responses lasting from 1 to
4 years. Children treated with rituximab for AIHA (n= 3) did not
respond. Noted toxicities included persistent neutropenia, long
lasting severe hypogammaglobulinemia.Many of these side effects
have lasted for more than 5 years after the rituximab infusions
in some of our ALPS-U patients. In our experience, rituximab-
induced prolonged hypogammaglobulinemia compounds the risk
of OPSI in asplenic individuals. We do not use rituximab in ALPS
patients until all other options are exhausted (12).
Hydroxychloroquine
There is always a role in select patients for use of old fash-
ioned yet familiarmedications like hydroxychloroquine, Dapsone,
Azathioprine, or 6mercaptopurine for steroid sparing purposes.
We have successfully managed two young female patients with
hydroxychloroquine alone at doses 200–400mg once daily as a
single agent for refractory cytopenias and avoided long-term use
of corticosteroids and other immunosuppressive agents for up to
7 years.
TPO Mimetic Agents
Both eltrombopag (Promacta) and Nplate (Romiplostim) have
been used in four of our patients. As highlighted in Table 1,
two of them with thrombocytopenia responded with long-term
remission for up to 4 years while on Promacta or Romiplostim and
the other two did not respond. One of them continues to require
both Promacta and MMF to maintain his platelet counts in a safe
range of 50–100,000.
Use of short bridging courses of corticosteroids in ALPS
patients, stabilizes their blood counts before commencing long-
term single agent therapy with MMF, sirolimus, or hydrox-
ychloroquine. One should not rely on them as a first-line
upfront single agent treatment for significant cytopenias. MMF
or sirolimus should be added to the therapy while they are being
slowly tapered off their corticosteroids. Treatment with these
agents should be commenced concomitantly with steroids within
a 2–4weeks period and dose adjusted over an 8- to 12-week period
Initial  treatment 
• oral prednisone (1-2mg/kg/day) for 1 week, then taper slowly over 8-12 weeks. 
No Response:  
IV methylprednisolone (5-10 mg/kg/day) X 3-7 days
± IVIG
 (dose and duration based on severity of cytopenia) 
Followed by oral prednisone (2mg/kg/day)  tapered slowly 
over 8-12 weeks
No Response: Consider Rituximab
Initial Response with breakthrough cytopenia  
during corticosteroid tapering 
(Hg <8, ANC <500, Platelets <50,000): 
Increase dose of oral prednisone to 1-2mg/kg/day and
commence slow taper  again over 8-12 weeks
AND 
Add oral mycophenolate mofetil (MMF)  
~1200mg/M2/day divided twice daily 
Plan to continue MMF long term 
Hypersplenism and No response to MMF: 
Consider Sirolimus or other chemotherapeutic and
immunosuppressive agents* 
Response to MMF with breakthrough cytopenia : 
Consider short term pulse dose of corticosteroid
(oral prednisone 1-2mg/kg/day or higher equivalent dose
up to 5mg/kg/day based on clinical severity of cytopenia) 
Continue MMF
No Response: Assess for Splenectomy** 
**If hypersplenism is a major contributor to cytopenia 
No Response: Consider Rituximab
No Response: Assess for Splenectomy** 
**If hypersplenism is a major contributor to cytopenia 
Initial Response with breakthrough cytopenia
during corticosteroid tapering 
(Hg <8, ANC <500, Platelets <50,000): 
Increase dose of oral prednisone to 1-2mg/kg/day and
commence slow taper  again over 8-12 weeks
AND 
Add oral mycophenolate mofetil (MMF)  
~1200mg/M2/day divided twice daily 
Plan to continue MMF long term 
Hypersplenism and Lack of sustained response to MMF:  
Consider Sirolimus or other chemotherapeutic and
immunosuppressive agents* 
FIGURE 1 | This schematic diagram is only a suggested guideline
for managing children with ALPS-associated autoimmune
multilineage cytopenias and is derived from our published work
(10). Use of G-CSF may be warranted for isolated neutropenia
associated with systemic infections. Similarly use of other
chemotherapeutic and immunosuppressive agents (e.g., vincristine,
methotrexate, mercaptopurine, azathioprine, cyclosporine,
hydroxychloroquine) besides mycophenolate mofetil (MMF) and sirolimus
(rapamycin) can also be considered as a steroid sparing measure. This
approach can be used for avoiding or at least postponing surgical
splenectomy at the discretion of the treating clinicians based on the
circumstances of a specific patient.
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while the corticosteroids are being tapered with periodic moni-
toring of CBC.Management algorithm for approaching treatment
decisions in ALPS patients is suggested in Figure 1 based on our
experience highlighted above and is modified from our previous
publication (10).
Discussion
Many individual ALPS patients have to be exposed to long-
term immunosuppression to remain free from their refractory
cytopenias. Risk–benefit ratio should be assessed before exposing
any patient to medications that might have long-term comorbidi-
ties. No significant iatrogenic end organ toxicities have been noted
in any of our patients who have followed with us while receiving
chronic therapy with MMF or sirolimus over the last 15 years. We
have not used prophylaxis for fungal infections or pneumocystis
jiroveci with fluconazole, septran (Bactrim), or pentamidine in
those patients that have been maintained successfully on long-
term therapy with MMF or sirolimus. There may be a role for
long-term use of thrombopoietin mimetic agents and histone
deacetylase inhibitors for managing recalcitrant cytopenias and
hypersplenism. Novel and non-toxic targeted lympholytic thera-
pies may become available in future to control the lymphoprolif-
erative processes resulting in cytopenias in childrenwith inherited
disorders of immune function.
Continued search for new genetic mutations in the subgroup
of ALPS patients with undetermined genetic defects (ALPS-U)
are underway at our institution using emerging genomic and cell
biology tools, includingwhole exome and genome sequencing and
analysis. Some novel immune dysregulatory syndromes have been
identified recently, leading to validation of candidate genes (e.g.,
RAS, CTLA4, LRBA, PI3Kinase, MagT1, STAT3-activating muta-
tions, etc.) in their pathogenesis (25–31). Each of these syndromes
is unique in some of their clinical presentations, while there is
considerable overlap in their presentation with ALPS and com-
mon variable immune deficiency (CVID) (30, 32). The inherited
genetic defect in them is not going to dissipate any time soon and
hence many of them shall require similar long-term approaches
for managing their clinical complications including autoim-
mune cytopenias as well as nodal and extranodal inflammatory
and infiltrative lymphoid lesions leading to other end organ
damage.
Conclusion
Pediatric patients with refractory autoimmune cytopenias despite
their normal bonemarrows often challenge our skills in both diag-
nosis and management. Patients with ALPS and related disorders
presenting with cytopenias often require long-term immunosup-
pressive therapies and consistent follow-up under care givers who
are familiar with them. Vigilance toward the toxic side effects
associatedwith each chosen therapeutic agent is imperative. These
children present unique challenges and should be managed by
harmonizing their diagnosis and care, including genetic counsel-
ing as needed for these emerging novel immunodysregulatory dis-
orders. These approaches have implications in terms of resource
allocation within the health care systems as the children of today
transition into adolescents and young adults of tomorrow. All of
them require monitoring and follow-up bymultiple subspecialists
familiar with their condition. It is desirable to not only utilize
existing registries like ESID and USIDNET but also develop inter-
national registries beyond Europe andNorth America for rare and
complex immune problems and chronic multilineage cytopenias
in order to improve their management by elucidating and sharing
their natural history while choosing rational therapies with local
context.
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